Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 335 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Drug Allergy Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants

NCT07088913
View directory record Official record
Conditions
Healthy Participants
Interventions
Capivasertib, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 27, 2026, 1:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Allergenicity of Hypoallergenic Peanut Product in Peanut Allergic Subjects

NCT01489514
View directory record Official record
Conditions
Peanut Allergy
Interventions
Epicutaneous skin prick testing
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 27, 2026, 1:46 PM EDT
Terminated Not applicable Interventional

Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Capecitabine Chemotherapy

NCT00767689
View directory record Official record
Conditions
Hand and Foot Syndrome
Interventions
Vitamin B 6, placebo
Drug
Lead sponsor
Cook County Health
Government
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 27, 2026, 1:46 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

NCT07723248
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
Rinzimetostat, Darolutamide, Enzalutamide, Docetaxel
Drug
Lead sponsor
ORIC Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
11
States / cities
Coral Springs, Florida • Jeffersonville, Indiana • Holland, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 27, 2026, 1:46 PM EDT
Completed Not applicable Interventional Results available

A Study Examining the Use of a Migraine Medicine in the Treatment of Two Migraine Attacks in Patients Who Have Increased Skin Sensitivity

NCT00203268
View directory record Official record
Conditions
Migraine
Interventions
dihydroergotamine mesylate
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 27, 2026, 1:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sex-related Differences in the Response to the Muscle Relaxant Drug Mivacurium

NCT01906528
View directory record Official record
Conditions
Muscle Relaxation, Sex
Interventions
Mivacurium
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2014 · Synced Oct 27, 2026, 1:46 PM EDT
Completed No phase listed Observational

Role of Inflammatory Mediators in AERD

NCT02824523
View directory record Official record
Conditions
Asthma, Aspirin-Induced
Interventions
aspirin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2022 · Synced Oct 27, 2026, 1:46 PM EDT
Completed Phase 2 Interventional

A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma

NCT02099656
View directory record Official record
Conditions
Asthma
Interventions
Lebrikizumab, Placebo, Inhaled corticposteroids (ICS), Second Asthma Controller Medication
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 27, 2026, 1:46 PM EDT
Not listed Early Phase 1 Interventional

Evaluating Efficacy of Smart Device in Assisting With Inhaler Technique and Adherence

NCT04250779
View directory record Official record
Conditions
Asthma, Adherence, Medication, Childhood Asthma
Interventions
CapMedic smart inhaler device, Video-based guidance
Device · Behavioral
Lead sponsor
Landon Pediatric Foundation
Other
Eligibility
8 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 27, 2026, 1:46 PM EDT
Recruiting Phase 2 Interventional

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

NCT07216027
View directory record Official record
Conditions
Atopic Dermatitis, Eczema, Atopic
Interventions
PF-08049820, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
17
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Huntington Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 27, 2026, 1:46 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection

NCT05732454
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Dermatitis, Unspecified, Eczema, Eczema, Atopic
Interventions
etrasimod, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
44
States / cities
Fountain Valley, California • Laguna Hills, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 27, 2026, 1:46 PM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

NCT02157883
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Interventions
Pharmacokinetic sampling, AZD9291, Itraconazole
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
2
States / cities
San Diego, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 27, 2026, 1:46 PM EDT
Completed Phase 2 Interventional

DOXIL for Consolidation Therapy in Ovarian Cancer.

NCT00248248
View directory record Official record
Conditions
Ovarian Neoplasm
Interventions
liposomal doxorubicin
Drug
Lead sponsor
Southeastern Gynecologic Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 27, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

NCT01867125
View directory record Official record
Conditions
Asthma
Interventions
Lebrikizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
53
States / cities
Pell City, Alabama • Tucson, Arizona • Fountain Valley, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 27, 2026, 1:46 PM EDT
Active, not recruiting Phase 3 Interventional

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT05445778
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
74
States / cities
Mobile, Alabama • Phoenix, Arizona • Irvine, California + 62 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 27, 2026, 1:46 PM EDT
Withdrawn Phase 4 Interventional

A Feasibility Study to Assess the Use of Gadolinium in Computed Tomography

NCT02163005
View directory record Official record
Conditions
Contrast Media Allergy
Interventions
Gadolinium
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
56 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 27, 2026, 1:46 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers

NCT05111262
View directory record Official record
Conditions
Asthma, Nonadherence, Medication
Interventions
Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 27, 2026, 1:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Use of the Propeller Health Platform to Improve Inhaled Corticosteroid (ICS) Use Among Adults With Uncontrolled Persistent Asthma

NCT03860519
View directory record Official record
Conditions
Asthma
Interventions
Electronic Medication Monitors on ICS and SABA - Active Mode, Electronic Medication Monitors on ICS and SABA - Silent Mode, Asthma App Tracking of ICS/SABA Usage - Active Mode, Asthma App Tracking of ICS/SABA Usage - Silent Mode, NorthShore Connect Real Time ICS and SABA Usage Feedback - Yes, NorthShore Connect Real Time ICS and SABA Usage Feedback - No, Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - Yes, Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - No
Behavioral
Lead sponsor
Endeavor Health
Other
Eligibility
25 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 27, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair

NCT00927758
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Gainesville, Florida • Iowa City, Iowa • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 27, 2026, 1:46 PM EDT
Recruiting Not applicable Interventional

Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation

NCT07396987
View directory record Official record
Conditions
Asthma Attack, Asthma Control, Asthma Exacerbations, Asthma
Interventions
ER-Initiated Telehealth Referral
Behavioral
Lead sponsor
Juan Carlos Cardet
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 27, 2026, 1:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants

NCT04545944
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vonoprazan, Midazolam
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 27, 2026, 1:46 PM EDT
Completed Phase 3 Interventional

Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis

NCT02896101
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus Cream, 1%, Elidel® (pimecrolimus) Cream, Placebo of Pimecrolimus Cream, 1%
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
12 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
27
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 27, 2026, 1:46 PM EDT
Completed Phase 3 Interventional

BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient

NCT05322707
View directory record Official record
Conditions
Asthma
Interventions
Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg, Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol, Placebo
Drug
Lead sponsor
Cipla Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 27, 2026, 1:46 PM EDT
Completed Not applicable Interventional

Increasing Adherence to Asthma Medication in Urban Teens

NCT00269282
View directory record Official record
Conditions
Asthma
Interventions
Self-Management Training, Motivational Interviewing (MI)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
10 Years to 15 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Oct 27, 2026, 1:46 PM EDT